EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (Amex: AIS) announced that it has signed a worldwide development and license agreement with an as yet undisclosed global pharmaceutical and consumer products company, with multi-billion dollar revenues. The planned product, in the field of opioid analgesia, will be delivered transmucosally using Antares’ proprietary EasyTec™ oral disintegrating tablet (ODT) delivery platform. Signing this agreement demonstrates successful completion of a feasibility agreement which was initiated in October 2006.
